首页> 美国卫生研究院文献>Canadian Respiratory Journal >Clara Cell Protein Expression in Mechanically Ventilated Term and Preterm Infants with Respiratory Distress Syndrome and at Risk of Bronchopulmonary Dysplasia: A Pilot Study
【2h】

Clara Cell Protein Expression in Mechanically Ventilated Term and Preterm Infants with Respiratory Distress Syndrome and at Risk of Bronchopulmonary Dysplasia: A Pilot Study

机译:机械通气足月和早产儿呼吸窘迫综合征并有支气管肺发育不良风险的Clara细胞蛋白表达:一项初步研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this pilot study was to determine Clara cell protein (CC16) concentration in bronchoalveolar lavages (BAL) fluid from full-term and preterm (<37 weeks' gestational age) neonates requiring respiratory support, having symptoms of neonatal respiratory distress syndrome, and at risk of bronchopulmonary dysplasia (BPD). We hypothesized that CC16 may be predictive of BPD diagnosis regardless of gestational age. BAL fluid CC16 was measured by ELISA at birth and at day 7 of life. Both groups that developed BPD showed significantly decreased BAL fluid CC16 levels compared to those infants that did not develop the disease. CC16 positively correlated with diagnosis of BPD and negatively with the severity of the disease. These results suggest that BAL fluid CC16 levels may have a diagnostic value at day 7 for BPD in both term and preterm infants. This study demonstrates the potential utility of BAL fluid CC16 levels as a biomarker for BPD in term infants.
机译:这项初步研究的目的是确定需要呼吸支持的足月和早产(胎龄小于37周的新生儿)的支气管肺泡灌洗液(BAL)中的Clara细胞蛋白(CC16)浓度,并有支气管肺发育不良(BPD)的风险。我们假设CC16可以预测BPD诊断,而与胎龄无关。在出生时和生命的第7天通过ELISA测量BAL液CC16。与未患该病的婴儿相比,患BPD的两组均显示BAL液CC16水平明显降低。 CC16与BPD的诊断呈正相关,与疾病的严重程度呈负相关。这些结果表明,足月和早产儿BAL液CC16水平在第7天对BPD可能具有诊断价值。这项研究证明了BAL液CC16水平作为足月儿BPD的生物标志物的潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号